- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial initiation date: Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers (clinicaltrials.gov) - Jun 12, 2019 P1/2, N=73, Not yet recruiting, These findings will be beneficial for optimizing the selection of specific HDACIs in medical fields such as pain medicine and neuropsychiatry. Initiation date: May 2019 --> Aug 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Epigenetic controller: Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents (clinicaltrials.gov) - Jun 5, 2019 P1b, N=27, Recruiting, Addition of ATRA to ED may potentiate inflammation and contribute to TNBC regression. Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- |||||||||| entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax
Journal: Research progress in the role of FBXW7 in drug resistance against non-small cell lung cancer (Pubmed Central) - May 31, 2019 The main mechanism is that FBXW7 mutation leads to drug resistance by reducing ubiquitination and degradation of its downstream proteins, including Snail protein, myeloid cell leukemia sequence 1 (MCL-1), mammalian target of rapamycin (mTOR), and coiled-coil-domain containing 6 (CCDC6). Rapamycin, histone deacetylase inhibitor MS-275, and rabdosia are effective in drug-resistant NSCLC patients with FBXW7 mutation.
- |||||||||| Zolinza (vorinostat) / Merck (MSD), entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax
Journal: Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells. (Pubmed Central) - May 31, 2019 The reduced migration and invasion of HDACis-treated U87 cells, at least in part, may account for the inhibition of tube formation. In conclusion, our results indicate that HDACis are promising candidates for blocking vascular mimicry in GBM.
- |||||||||| molibresib (GSK525762) / GSK, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial initiation date, Metastases: Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas (clinicaltrials.gov) - May 29, 2019 P1, N=49, Not yet recruiting, HDAC1 could serve as a novel hepcidin suppressor by binding to SMAD4, which effect is independent of BMP/SMAD1/5/8 signaling. Initiation date: May 2019 --> Sep 2019
- |||||||||| RGFP966 / BioMarin, CRA-026440 / Quest Diagnostics, entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax
Journal: Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells. (Pubmed Central) - May 15, 2019 We observed that RGFP966 and PCI34051 increased DR4 expression after incubation on DLD-1 cells, while RGFP966 induced more DR5 expression on WiDr cells, indicating a different role for DR4 or DR5 in these combinations. At last, we show that combined treatment of RGFP966 with TRAIL variants (rhTRAIL 4C7/DHER) increases apoptosis on 3D tumor spheroid models.
- |||||||||| Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov) - May 7, 2019 P1/2, N=45, Active, not recruiting, N=162 --> 94 Trial primary completion date: Feb 2019 --> Jun 2019
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: EOC103A3101: Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 7, 2019 P3, N=327, Recruiting, Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Jul 2018 N=512 --> 327 | Trial completion date: Apr 2023 --> Aug 2021 | Trial primary completion date: Oct 2020 --> Feb 2021
- |||||||||| entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax Pharma
Journal, Heterogeneity: Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review. (Pubmed Central) - Apr 23, 2019 Interestingly, salinomycin was the only drug that effectively killed all three cancer cell subpopulations, irrespective of their capacity of stemness. Further, Scheme 2D/3D/mammosphere may be a useful model to accelerate the screening for curative cancer drugs while avoiding costly characterization of compounds that may have only selective toxicity to some, but not all, cancer cell subpopulations.
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P1/2 trial: Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers (clinicaltrials.gov) - Apr 22, 2019 P1/2, N=73, Not yet recruiting,
- |||||||||| Jingzhuda (entinostat) / Syndax Pharma, EOC Pharma
Trial completion date, Trial primary completion date, Combination therapy, Epigenetic controller: A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Apr 20, 2019 P2, N=108, Recruiting, Further, Scheme 2D/3D/mammosphere may be a useful model to accelerate the screening for curative cancer drugs while avoiding costly characterization of compounds that may have only selective toxicity to some, but not all, cancer cell subpopulations. Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Feb 2019 --> Sep 2019
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Enrollment closed, Enrollment change, Metastases: Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer (clinicaltrials.gov) - Apr 20, 2019 P2, N=58, Active, not recruiting, Trial completion date: Feb 2019 --> Dec 2019 | Trial primary completion date: Feb 2019 --> Sep 2019 Completed --> Active, not recruiting | N=40 --> 58
- |||||||||| entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax
Journal: CONSOLIDATION OF AN AVERSIVE TASTE MEMORY REQUIRES TWO ROUNDS OF TRANSCRIPTIONAL AND EPIGENETIC REGULATION IN THE INSULAR CORTEX. (Pubmed Central) - Apr 18, 2019 The present results show that transcription inhibition immediately and 7 hours after acquisition impairs the CTA memory consolidation, whereas the inhibition of histone deacetylation strengths this memory at those temporal windows. These findings reveal that CTA memory requires recurrent rounds of transcriptional modulation events in the IC in order to consolidate this memory trace, demonstrating that transcriptional and epigenetic modulation substantially contribute to memory-consolidation-related functions performed by a neocortical area even several hours after memory acquisition.
- |||||||||| entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax
Journal: Notch Inhibition Promotes Differentiation of Liver Progenitor Cells into Hepatocytes via sox9b Repression in Zebrafish. (Pubmed Central) - Apr 18, 2019 ...We have recently shown in a zebrafish model of LPC-driven liver regeneration that inhibition of Hdac1 activity through MS-275 treatment enhances sox9b expression in LPCs and impairs LPC-to-hepatocyte differentiation...Hepatocyte ablation in sox9b heterozygous mutant embryos enhanced Hnf4a induction, while BEC-specific Sox9b overexpression impaired LPC-to-hepatocyte differentiation. Our results establish the Notch-Sox9b signaling axis as inhibitory to LPC-to-hepatocyte differentiation in a well-established in vivo LPC-driven liver regeneration model.
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial initiation date: A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 16, 2019 P1, N=24, Not yet recruiting, Our results establish the Notch-Sox9b signaling axis as inhibitory to LPC-to-hepatocyte differentiation in a well-established in vivo LPC-driven liver regeneration model. Initiation date: Nov 2018 --> Jul 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Trial primary completion date, Combination therapy: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas (clinicaltrials.gov) - Apr 8, 2019 P2, N=78, Recruiting, Initiation date: Nov 2018 --> Jul 2019 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020
- |||||||||| entinostat (SNDX-275) / Kyowa Hakko Kirin, Syndax
Journal: Entinostat Helps Thwart Immunotherapy Resistance. (Pubmed Central) - Apr 4, 2019 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Jun 2020 Findings from the ENCORE-601 trial's melanoma cohort show that the experimental HDAC inhibitor entinostat is well tolerated and, together with pembrolizumab, induces durable responses in patients whose disease has progressed on PD-1 blockade alone.
- |||||||||| Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion date, Trial primary completion date, Metastases: Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer (clinicaltrials.gov) - Mar 12, 2019 P1, N=15, Active, not recruiting, MS-275 critically regulates RUNX2 transactivation in VICs through both canonical and non-canonical Wnt signaling pathways. Trial completion date: Feb 2019 --> Dec 2021 | Trial primary completion date: Feb 2019 --> Dec 2021
- |||||||||| Avastin (bevacizumab) / Roche, Jingzhuda (entinostat) / EOC Pharma, EddingPharm, Tecentriq (atezolizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Jan 31, 2019 P1/2, N=62, Recruiting, Trial completion date: Feb 2019 --> Feb 2020 | Trial primary completion date: Jan 2019 --> Jan 2020 Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2019 --> Jan 2020
|